JDRF Announces New Executive Vice President of Research and Advocacy


JDRF announced today its new executive vice president of research and advocacy, David E. Wheadon, M.D. Dr. Wheadon brings 26 years of experience as a highly effective leader in drug development and translational research, regulatory and medical affairs, and patient advocacy. In this new position, he will work closely with JDRF’s president and CEO, Jeffrey Brewer, and the senior leadership of JDRF’s research and advocacy teams, overseeing all aspects of the organization’s efforts to accelerate the discovery, development, and delivery of life-changing therapies for type 1 diabetes (T1D).

“After conducting an international search for candidates to fill this important new role for JDRF, we found a perfect match in Dr. Wheadon’s distinguished medical and research background, his deep knowledge of the regulatory process, and his demonstrated ability to build alliances and manage teams,” Mr. Brewer said.

Dr. Wheadon joins JDRF’s leadership team after serving as senior vice president of scientific and regulatory affairs at Pharmaceutical Research and Manufacturers of America. There, he provided strategic leadership in setting the scientific and regulatory advocacy agenda for the biopharmaceutical industry, and built and strengthened collaborative alliances.

A graduate of Harvard College with a doctor of medicine from Johns Hopkins University, Dr. Wheadon has worked in leadership roles with major pharmaceutical companies, including: vice president of global pharmaceutical regulatory and medical sciences at Abbott Laboratories; senior vice president of U.S. regulatory affairs at GlaxoSmithKline Pharmaceuticals; and clinical research physician at Eli Lilly, where he was integral to the successful development and approval of several important drugs for central nervous system diseases, diabetes, gastrointestinal disorders, and diseases in other therapeutic areas.

Mr. Brewer continued: “Dr. Wheadon’s broad exposure to industry, government, the Food and Drug Administration, academia, and influential policy and decision makers—along with his world-class research training and credentials—cover all the aspects of the translational research pipeline where JDRF works today. Under his leadership, we look forward to expanding JDRF’s capabilities and increasing our emphasis on exciting translational opportunities that hold the most promise to improve the lives of people with type 1 diabetes in the next decade, on our way to a future where this disease is spoken about in the past tense.”

Notify of
Inline Feedbacks
View all comments
Copyright © 2009-2021 Diabetes Media Foundation, All Rights Reserved.
ASweetLife™ is a trademark of the Diabetes Media Foundation, All Rights Reserved.
Would love your thoughts, please comment.x